Evusheld authorized by Health Canada
On April 14, Evusheld – the only pre-exposure long-acting monoclonal antibody for COVID-19 prevention – was authorized by Health Canada and recently supported with broad recommendations for use in immune-compromised Canadians by the Canadian Agency for Drugs and Technologies in Health and Institut national d’excellence en santé et en services sociaux.
Provinces and territories are currently releasing their own jurisdictional guidance on who is eligible and how to access Evusheld. To support you and the patients you represent, the Canadian Public Health Association has a developed an online resource centre with up-to-date information for patients and healthcare providers on preventive long-acting monoclonal antibodies, including:
- Links to the most recent provincial/territorial guidance on who can receive Evusheld and how;
- Resources for immune-compromised Canadians, including information about long-acting monoclonal antibodies;
- Information for health professionals to support decision-making discussions with patients.
Please visit https://www.cpha.ca/laab to learn more and check back often as content will be updated and added as new information becomes available.